Pimecrolimus cream 1%
Sponsors
Novartis, Par Pharmaceutical, Inc., National Medical Research Center for Children's Health, Russian Federation
Conditions
Atopic DermatitisAtopic EczemaChronic Hand Dermatitis
Phase 3
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
CompletedNCT00226707
Start: 2004-07-31End: 2005-03-31Target: 652Updated: 2008-02-15
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
CompletedNCT00232011
Start: 2004-05-31End: 2005-05-31Target: 160Updated: 2007-12-17
Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
CompletedNCT03297502
Start: 2016-06-30End: 2017-06-30Updated: 2017-09-29
Phase 4
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
CompletedNCT00150059
Start: 2004-12-31End: 2005-12-31Updated: 2008-02-15
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
CompletedNCT00367393
Start: 2006-03-31End: 2007-12-31Updated: 2017-02-24
A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
CompletedNCT00484003
Start: 2004-10-31End: 2004-12-31Updated: 2008-02-15
Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life
CompletedNCT04900948
Start: 2017-12-10End: 2020-04-25Updated: 2021-05-27